<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2007-7459</journal-id>
<journal-title><![CDATA[Horizonte sanitario]]></journal-title>
<abbrev-journal-title><![CDATA[Horiz. sanitario]]></abbrev-journal-title>
<issn>2007-7459</issn>
<publisher>
<publisher-name><![CDATA[Universidad Juárez Autónoma de Tabasco, División Académica de Ciencias de la Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2007-74592020000200195</article-id>
<article-id pub-id-type="doi">10.19136/hs.a19n2.3623</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Costo-efectividad incremental del Palivizumab en prematuros en la Seguridad Social de Costa Rica]]></article-title>
<article-title xml:lang="en"><![CDATA[Incremental cost- effectiveness of palivizumab in premature at Costa Rican Social Security]]></article-title>
<article-title xml:lang="pt"><![CDATA[Custo-efetividade incremental do palivizumabe em prematuros da Previdência Social da Costa Rica]]></article-title>
<article-title xml:lang="fr"><![CDATA[Coût-efficacité incrémental du Palivizumab chez les prématurés de la Sécurité Sociale du Costa Rica]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jiménez Herrera]]></surname>
<given-names><![CDATA[Luis Guillermo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Collado Herrera]]></surname>
<given-names><![CDATA[Manuel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gálvez González]]></surname>
<given-names><![CDATA[Ana María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Costa Rica Instituto de Investigaciones Farmacéuticas INIFAR ]]></institution>
<addr-line><![CDATA[San José ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Nacional de Higiene,Epidemiologia y Microbiología (INHEM) Departamento de Servicios de Salud ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Escuela Nacional de Salud Pública Departamento de Economía de la Salud ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2020</year>
</pub-date>
<volume>19</volume>
<numero>2</numero>
<fpage>195</fpage>
<lpage>207</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2007-74592020000200195&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2007-74592020000200195&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2007-74592020000200195&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo  Estimar la eficiencia mediante el análisis costo-efectividad incremental de la terapia con Palivizumab contra la práctica clínica habitual en el período 2010-2017.  Materiales y Métodos  Se realizó una evaluación económica completa del tipo costo-efectividad y el horizonte temporal fue de un año (sin tasa de descuento). El estudio considero la perspectiva de la Seguridad Social, se incluyeron siete hospitales y las variables de efectividad se seleccionaron a partir de la información disponible en la literatura científica. Los costos se expresaron en dólares americanos para cada año. Se hizo el análisis árbol de decisiones con los datos agrupados y el análisis costo-efectividad medio e incremental de sensibilidad al considerar la edad gestacional como variable clasificadora. Se consideraron los principios éticos pertinentes.  Resultados  Se encontraron datos de 200 prematuros con Palivizumab y 206 sin la administración del tratamiento. El análisis del árbol de decisiones mostró un costo efectividad incremental de US$1,799.00. El costo-efectividad medio fue más alto en prematuros con Palivizumab y el costo-efectividad incremental en el sub grupo de 32 a 35 semanas resultó el de más costo-efectivo. Al intervalo de confianza del 90 y 95%, el rango del valor promedio del costo total del tratamiento es amplio por lo que el costo es sensible al cambio.  Conclusiones  El Palivizumab es mayor en costo-efectivo en prematuros de 32 a 35 semanas de edad gestacional.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective  To estimate the efficiency by incremental cost effectiveness analysis of palivizumab therapy against the usual clinical practice in 2010-2017 period.   Materials and methods  A complete economic evaluation of the cost effectiveness type was carried out and the time horizon was one year, without discount rate, the study was carried out from the perspective of Social Security, seven hospitals were included and the effectiveness variables were selected from the available information in the literature scientifically, the costs were expressed in US dollars for each year. The decision tree analysis was carried out with the grouped data and the average and incremental cost effectiveness and sensitivity analysis when considering gestational age as a classification variable. Relevant ethical principles were considered.  Results  Data of 200 premature infants were found with palivizumab and 206 without the administration of this treatment. The decision tree analysis showed an incremental cost effectiveness of US $ 1,799. The average cost effectiveness was higher in premature infants with palivizumab and the incremental cost effectiveness in the subgroup 32-35 weeks was the most effective cost. At the 90 and 95% confidence interval, the range of the average value of the total treatment cost is wide, so the cost is sensitive to change.  Conclusions  Palivizumab is more effective cost in premature of 32-35 weeks of gestational age.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Objetivo  Estimar a eficiência através da análise de custo-efetividade incremental da terapia com Palivizumab em relação à prática clínica habitual no período 2010-2017.  Materiais e Métodos  Foi realizada uma avaliação econômica completa do tipo custo-efetividade e o horizonte temporal foi de um ano (sem taxa de desconto). O estudo considerou a perspectiva da Previdência Social, sete hospitais e as variáveis de efetividade foram incluídas foram selecionados a partir das informações disponíveis na literatura científica. Os custos foram expressos em dólares americanos para cada ano. A análise da árvore de decisão foi feita com os dados agrupados e a análise de custo-efetividade média e incremental da sensibilidade a considere a idade gestacional como uma variável classificatória. Princípios éticos relevantes foram considerados.  Resultados  Foram encontrados dados de 200 bebês prematuros com Palivizumab e 206 sem administração do tratamento. A análise da árvore de decisão mostrou um custo incremental de $1.799,00. O custo-benefício médio foi maior em prematuros com Palivizumab, e o custo-efetividade incremental no subgrupo de 32 a 35 semanas foi o mais econômico. No intervalo de confiança de 90 e 95%, a faixa do valor médio do custo total do tratamento é ampla, tornando o custo sensível à mudança.  Conclusões  O palivizumabe é mais econômico em prematuros de 32 a 35 semanas de idade gestacional.]]></p></abstract>
<abstract abstract-type="short" xml:lang="fr"><p><![CDATA[Résumé  Objectif  Estimer l&#8217;efficience, au moyen de l'analyse coût-efficacité incrémental, du traitement par Palivizumab par rapport à la pratique clinique habituelle au cours de la période 2010-2017.  Méthodologie Une évaluation économique complète de type coût-efficacité a été réalisée sur un horizon temporel d'un an (sans taux d'actualisation). L'étude a été réalisée dans le contexte de la Sécurité Sociale. Sept hôpitaux ont été inclus et les variables d'efficacité ont été sélectionnées sur la base des informations disponibles dans la littérature scientifique. Les coûts ont été exprimés en dollars américains par an. L'analyse de l'arbre de décisions a été réalisée avec les données groupées, ainsi que l'analyse du rapport coût-efficacité moyen et incrémental de sensibilité en considérant l'âge gestationnel comme variable de classification. Les principes éthiques pertinents ont été appliqués.  Résultats  Des données concernant 200 nourrissons prématurés traités avec Palivizumab et 206 sans ce traitement ont été réunies. L'analyse de l'arbre de décisions a montré un coût-efficacité incrémental de 1 799 $ US. Le rapport coût-efficacité moyen a été plus élevé chez les nourrissons prématurés avec Palivizumab et le coût-efficacité incrémental dans le sous-groupe de 32 à 35 semaines a été le plus rentable. Avec un intervalle de confiance de 90 et 95%, la fourchette de la valeur moyenne du coût total du traitement est large, de sorte que le coût est sensible au changement.  Conclusions  Le Palivizumab est plus rentable chez les bébés prématurés de 32 à 35 semaines d'âge gestationnel.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Palivizumab]]></kwd>
<kwd lng="es"><![CDATA[costo-efectividad]]></kwd>
<kwd lng="es"><![CDATA[seguridad social]]></kwd>
<kwd lng="es"><![CDATA[virus sincitial respiratorio]]></kwd>
<kwd lng="en"><![CDATA[Palivizumab]]></kwd>
<kwd lng="en"><![CDATA[Cost-effectiveness]]></kwd>
<kwd lng="en"><![CDATA[Social security]]></kwd>
<kwd lng="en"><![CDATA[Respiratory syncytial virus]]></kwd>
<kwd lng="pt"><![CDATA[Palivizumab]]></kwd>
<kwd lng="pt"><![CDATA[custo-efetividade]]></kwd>
<kwd lng="pt"><![CDATA[Segurança social]]></kwd>
<kwd lng="pt"><![CDATA[vírus sincicial respiratório]]></kwd>
<kwd lng="fr"><![CDATA[Palivizumab]]></kwd>
<kwd lng="fr"><![CDATA[analyse coûts-bénéfices (rentabilité)]]></kwd>
<kwd lng="fr"><![CDATA[sécurité sociale]]></kwd>
<kwd lng="fr"><![CDATA[virus respiratoire syncytial]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nolan]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Borja]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Wecks]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ulloa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lazcano]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence and incidence of respiratory syncytial virus and other respiratory viral infections in children aged 6 months to 10 years with influenza like illness enrolled in randomized trial]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2015</year>
<volume>60</volume>
<page-range>80</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gimferrer]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Campins]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Codina]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rodrigo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Melendo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Martín]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Circulation of a novel human respiratory syncytial virus Group B genotype during the 2014-2015 season in Catalonia (Spain)]]></article-title>
<source><![CDATA[Clin Microbiol Infect.]]></source>
<year>2016</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>97-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Borroto]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Acost]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Valdés]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vigilancia de infecciones respiratorias aguda en Cuba, semanas de la 9-12.]]></article-title>
<source><![CDATA[BOLIPK]]></source>
<year>2017</year>
<volume>27</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>121-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bruning]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Leeflang]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vos]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Spijker]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[de Jong]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wolthers]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rapid tests for influenza, respiratory syncytial virus, and other respiratory viruses: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2017</year>
<volume>65</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1026-32</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sarna]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lambert]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sloots]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Whiley]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Alsaleh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mhango]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Viruses causing lower respiratory symptoms in young children: findings from the ORChID birth cohort.]]></article-title>
<source><![CDATA[Thorax]]></source>
<year>2018</year>
<volume>73</volume>
<page-range>969-79</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gonzales]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Lake]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[LaFleur]]></surname>
<given-names><![CDATA[J. Synagis]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[for respiratory syncytial virus prophylasis]]></article-title>
<source><![CDATA[UTAH, USA: Medicaid Dur Report;]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olchansky]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Hansen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pope]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[D´Cruz]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Fergie]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Goldstein]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Palivizumab prophylaxis for Respiratory Syncytial Virus: Examining the evidence around value]]></article-title>
<source><![CDATA[Open Forum Infections Diseases]]></source>
<year>2018</year>
<volume>5</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>ofy031</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sharif]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sharif]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Sharif]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Su]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Sharif]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[RSV infection in Nunavut cost analysis and associated risk factors: implication of vaccination program and public health planning]]></article-title>
<source><![CDATA[Vaccines and Immunol Open Access J]]></source>
<year>2018</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>26-36</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Broadbent]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Groves]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Shields]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Power]]></surname>
<given-names><![CDATA[U.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials.]]></article-title>
<source><![CDATA[Influenza and Other Respiratory Viruses.]]></source>
<year>2015</year>
<volume>9</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>169-78</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wen]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Mousa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bates]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lamb]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Crowe]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jardetzky]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Structural basis for antibody cross neutralization of respiratory syncytial virus and human metapneumovirus]]></article-title>
<source><![CDATA[Nat Microbiol]]></source>
<year>2016</year>
<volume>2</volume>
<page-range>16272</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Claydon]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sur]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Callejas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ladd]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kwan]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen]]></article-title>
<source><![CDATA[PloS one]]></source>
<year>2017</year>
<volume>12</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Griffiths]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Drews]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Marchant]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Respiratory syncytial virus: infection, detection, and new options for prevention and treatment]]></article-title>
<source><![CDATA[Clin Microbiol]]></source>
<year>2017</year>
<volume>30</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>277-319</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vielma]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Buelvas]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Suárez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gutiérrez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Chirinos]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Esfuerzos para el desarrollo de vacunas y adyuvantes]]></article-title>
<source><![CDATA[Acta Bioclinica]]></source>
<year>2018</year>
<volume>8</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>259-87</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Viegas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Goya]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mistchenko]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sixteen years of evolution of human respiratory sycytial virus subgroup A in Buenos Aires, Argentina: GA2 the prevalent genotype through the years]]></article-title>
<source><![CDATA[Infection, genetics and evolution]]></source>
<year>2016</year>
<volume>43</volume>
<page-range>213-21</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giersing]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Karron]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Vekemans]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kaslow]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Moorthy]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Meeting report: WHO consultation on respiratory syncytial virus (RSV) vaccine development, Geneva, 25-26 april 2016.]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2017</year>
<volume>37</volume>
<numero>50</numero>
<issue>50</issue>
<page-range>7355-62</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lihue]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Goya]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Orellana]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sancilio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Montali]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Unravelling respiratory syncytial virus outbreaks in Buenos Aires, Argentina: Molecular basis of the spatio-temporal transmission]]></article-title>
<source><![CDATA[Virology]]></source>
<year>2017</year>
<volume>508</volume>
<page-range>118-26</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camps]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Calzado Begue]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Galano Guzmán]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Perdomo Hernández]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Infecciones respiratorias agudas pediátricas. Un acercamiento a bronquiolitis]]></article-title>
<source><![CDATA[Inf Cient]]></source>
<year>2015</year>
<volume>90</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>391-400</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Brenes]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mortalidad en menores de cinco años en Costa Rica 1920-2009]]></article-title>
<source><![CDATA[costarric. salud pública]]></source>
<year>2017</year>
<volume>26</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>11-21</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gonzalez]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características clínicas y epidemiológicas de niños menores de dos años con bronquiolitis en el Hospital Nacional Dos de Mayo]]></article-title>
<source><![CDATA[Carriónica]]></source>
<year>2017</year>
<volume>4</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>8-29</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goldstein]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pediatric hospitalizations associated with respiratory syncytial virus (RSV) and influenza, and the frequency of asthma as a secondary diagnosis]]></article-title>
<source><![CDATA[BioRxiv]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cuéllar]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Guzmán]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudio descriptivo de reacciones adversas y problemas relacionados al medicamento por Palibizumab reportadas al Programa Distrital de Farmacovigilancia Bogotá, 2014-2016]]></article-title>
<source><![CDATA[Colombia: UDCA]]></source>
<year>2017</year>
<page-range>100</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Geoghegan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Erviti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Caballero]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vallone]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Zanone]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Losada]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mortality due to respiratory syncytial virus. Burden and risk factors.]]></article-title>
<source><![CDATA[Am J Respir Crit Care Med]]></source>
<year>2017</year>
<volume>195</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>96-103</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fauroux]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Simões]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Checchia]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Paes]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Figueras]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Manzoni]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The burden and long-term respiratory morbidity associated with respiratory syncytial virus infection in early childhood]]></article-title>
<source><![CDATA[Infect Dis Ther]]></source>
<year>2017</year>
<volume>6</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>173-97</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krilov]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Palazzi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Fernandez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Klein]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mahadevia]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of respiratory syncytial virus risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States]]></article-title>
<source><![CDATA[Value in Health.]]></source>
<year>2010</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>77-86</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Langjhar]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sotelo]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Presente y futuro de los anticuerpos recombinantes terapéuticos]]></article-title>
<source><![CDATA[Mem. Inst. Invest. Cienc. Salud]]></source>
<year>2016</year>
<volume>14</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>110-21</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[OlickerA]]></surname>
<given-names><![CDATA[Li H]]></given-names>
</name>
<name>
<surname><![CDATA[Tatsuoka C]]></surname>
<given-names><![CDATA[Ross K]]></given-names>
</name>
<name>
<surname><![CDATA[TrembathA]]></surname>
<given-names><![CDATA[Hibbs M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Have changing palivizumab administration policies led to more respiratory morbidity in infants born at 32-35 weeks?]]></article-title>
<source><![CDATA[J Pediatr]]></source>
<year>2016</year>
<volume>171</volume>
<page-range>31-7</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tulloh R]]></surname>
<given-names><![CDATA[Medrano C]]></given-names>
</name>
<name>
<surname><![CDATA[Checchia P]]></surname>
<given-names><![CDATA[Stapper.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CHD and respiratory syncytial virus: global expert exchange recommendations]]></article-title>
<source><![CDATA[Cardiol Young.]]></source>
<year>2017</year>
<volume>27</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1504-21</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<collab>United Health Care Oxford.</collab>
<article-title xml:lang=""><![CDATA[Synagis (Palivizumab)]]></article-title>
<source><![CDATA[Oxford: Pharmacy UHC]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Albas]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Satragno]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Cattaino]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rubio]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recomendaciones sobre el uso de palivizumab. Actualización 2015]]></article-title>
<source><![CDATA[Arch Argent Pediatr]]></source>
<year>2016</year>
<volume>114</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>84-8</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<collab>American Academy of Pediatrics Committee on Infectious Diseases</collab>
<article-title xml:lang=""><![CDATA[Updated Guidance for Palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection]]></article-title>
<source><![CDATA[PEDIATRICS]]></source>
<year>2014</year>
<volume>134</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>415-20</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vaccine development for respiratory syncytial]]></article-title>
<source><![CDATA[virus. Currentopinion inVirology]]></source>
<year>2017</year>
<volume>23</volume>
<page-range>107-12</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kwok]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ng]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hon]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Palivizumab for Infants &lt; 29 Weeks in Hong Kong without a Clear-Cut Season for Respiratory Syncytial Virus Infection-A Cost-Effectiveness Analysis. J]]></article-title>
<source><![CDATA[Trop Pediatrics]]></source>
<year>2017</year>
<volume>0</volume>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chow]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chicella]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Christensen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Moneymaker]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Harrington]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dice]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improving Palivizumab Compliance rough a Pharmacist-Managed RSV Prevention Clinic]]></article-title>
<source><![CDATA[J Pediatr Pharmacol Ther]]></source>
<year>2017</year>
<volume>22</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>338-43</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Resch]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Egger]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kurath-Koller]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Urlesberger]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Respiratory syncytial virus hospitalizations in infants of 28- week gestational age and less in the palivizumab era.]]></article-title>
<source><![CDATA[Intern J Infect Disease]]></source>
<year>2017</year>
<volume>30</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>50-3</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="">
<collab>Ministerio de Salud</collab>
<source><![CDATA[Lineamiento técnico: Prevención de la infección respiratoria aguda grave por virus sincitial respiratorio en pediatría. Anticuerpo monoclonal específico Palivizumab]]></source>
<year>2014</year>
<page-range>18</page-range><publisher-loc><![CDATA[Argentina ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cetinkaya]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Oral]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Karatekin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cebeci]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Babayigit]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Yesil]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in Ge preterm infants: determination of the ideal target population for prophylaxis]]></article-title>
<source><![CDATA[Eur J Clin Microbiol Infect Dis.]]></source>
<year>2017</year>
<volume>8</volume>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Drummond]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Principios de evaluación económica en asistencia sanitaria]]></source>
<year>1983</year>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Servicios de Publicaciones Ministerio de Trabajo y Seguridad Social;]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Drummond]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Stoddart]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Torrance]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Métodos para la evaluación económica de los programas de atención de la salud]]></source>
<year>1991</year>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Díaz de Santos;]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Angelis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lange]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kanavos]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries]]></article-title>
<source><![CDATA[Europ J Health Economic]]></source>
<year>2018</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>123-52</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calvo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pelegrín]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gil Basulto]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enfoques teóricos para la evaluación de la eficiencia y eficacia en el primer nivel de atención médica de los servicios de salud del sector público.]]></article-title>
<source><![CDATA[Retos de la Dirección]]></source>
<year>2018</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>96-118</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lessa]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Caccavo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Curti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ouimet]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lembruger]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fortalecimiento y evaluación de tecnologías sanitarias y del proceso de toma de decisiones en América Latina.]]></article-title>
<source><![CDATA[Panam Salud Pública]]></source>
<year>2017</year>
<volume>41</volume>
<page-range>1-11</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cabo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cabo]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Bellmont]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Herreros]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Trainini]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medicine based on Efficiency-Based Medicine (Cost- Effectiveness and Cost-Utility) Supporting Evidence-Based Medicine]]></article-title>
<source><![CDATA[Argentine J Cardiol]]></source>
<year>2018</year>
<volume>86</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>218-23</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boyadyjian]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Notejane]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Assandri]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pujadas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pírez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bronquiolitis en neonatos. Experiencia de cuatro años en un hospital pediátrico de referencia nacional]]></article-title>
<source><![CDATA[Arch Pediatr Urug.]]></source>
<year>2015</year>
<volume>86</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>265-72</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calderón]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Prevalencia y complicaciones pulmonares asociadas a ventilación mecánica en recién nacidos ingresados en el área de neonatología del Hospital Municipal de la Mujer y el Niño]]></source>
<year>2017</year>
<page-range>62</page-range><publisher-loc><![CDATA[Ecuador ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Católica de Cuenca]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camps]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Calzado]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Galano]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Perdomo]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Infecciones respiratorias agudas pediátricas. Un acercamiento a bronquiolitis]]></article-title>
<source><![CDATA[Inf Cient]]></source>
<year>2015</year>
<volume>90</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>391-400</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Choueiry]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gerbaka]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hanna]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Fenianos]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost effectiveness of palivizumab in prevention against RSV hospitalizations in risk groups]]></article-title>
<source><![CDATA[J Pediatr Care.]]></source>
<year>2016</year>
<volume>2</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>19</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fulgencio]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Bronquiolitis aguda inducida por virus. Análisis de las hospitalizaciones en el Hospital Universitario Donostia]]></source>
<year>2017</year>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Universidad del País Vasco]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Glick]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kjelleren]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hofstetter]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Subramony]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[RSV hospitalizations in comparison with regional RSV activity and inpatient palivizumab administration, 2010-2013.]]></article-title>
<source><![CDATA[Hosp pediatr]]></source>
<year>2017</year>
<volume>7</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>271-80</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Butt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dix]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Paes]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Respiratory syncytial virus (RSV) infection in children with medical complexity.]]></article-title>
<source><![CDATA[Eur J Clin Microbiol Infect Dis]]></source>
<year>2019</year>
<volume>38</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>171-6.</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Complicaciones de la ventilación mecánica en los neonatos de la unidad de cuidados intensivos neonatales]]></source>
<year>2018</year>
<page-range>50</page-range><publisher-loc><![CDATA[Ecuador ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Guayaquil, Facultad de Ciencias Médicas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Capizzi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Silvestri]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Orsi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cutrera]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rossi]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Sacco]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence]]></article-title>
<source><![CDATA[Italian journal of pediatrics]]></source>
<year>2017</year>
<volume>43</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>71-5</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yekta M]]></surname>
<given-names><![CDATA[Mutlu B]]></given-names>
</name>
<name>
<surname><![CDATA[Kavurt S]]></surname>
<given-names><![CDATA[YagmurA]]></given-names>
</name>
<name>
<surname><![CDATA[Demirel N]]></surname>
<given-names><![CDATA[Akyol M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Respiratory syncytial virus prophylaxis in preterm infants: a cost effectiveness study in Turkey]]></article-title>
<source><![CDATA[TurkJ Pediatr]]></source>
<year>2012</year>
<volume>54</volume>
<page-range>344-51</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ginsberg]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Somekh]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Schlesinger]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Should we use palivizumab immunoprophylaxis for infants against respiratory syncytial virus? a cost utility analysis]]></article-title>
<source><![CDATA[Journal of Health Policy Research]]></source>
<year>2018</year>
<volume>7</volume>
<numero>63</numero>
<issue>63</issue>
<page-range>1-14</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salinas]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Reyes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Garduño]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Granados]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost effectiveness analysis of the use of pavilizumab in the prophylaxis of preterm patients in México.]]></article-title>
<source><![CDATA[Salud Pública Méx]]></source>
<year>2012</year>
<volume>54</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>47-59</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shahabi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Peneva]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Incerti]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[McLaurin]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Stevens]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assesing variation in the cost of palivizumab for Respiratory Syncytial Virus prevention in preterm infants.]]></article-title>
<source><![CDATA[Pharmacoeconomics Open]]></source>
<year>2018</year>
<volume>2</volume>
<page-range>53-61</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
